Transfection Reagents: Key Tools in Molecular Biology Research and Gene Therapy
Transfection Reagents: Key Tools in Molecular Biology Research and Gene Therapy
In modern molecular biology and gene therapy, transfection reagents play an indispensable role. They enable efficient delivery of exogenous nucleic acids (such as DNA and RNA) into eukaryotic cells to achieve gene expression, silencing, or editing, thereby providing powerful technical support for probing gene function, disease mechanisms, and developing new therapeutic strategies. With the rapid progress of biotechnology, the repertoire of transfection reagents has expanded and their performance continues to be refined, allowing them to meet diverse research scenarios and application requirements.
I. Overview of Transfection and Delivery Systems
1.1 Basic Concept of Transfection
Transfection refers to the process of introducing exogenous nucleic acids into eukaryotic cells under in vitro culture conditions, where they are then expressed or exert their biological function. Common nucleic acid formats include expression or cloning plasmids, reporter gene plasmids, siRNA/shRNA, miRNA, mRNA, and plasmids, mRNA, or protein–RNA complexes used for CRISPR/Cas systems.
Compared with virus-mediated “transduction,” chemical transfection does not rely on viral particles. It is simpler, more flexible, and shorter in cycle time, making it suitable for routine in vitro experiments and high-throughput screening.
1.2 Core Functions of Transfection Reagents
The core function of a transfection reagent is to alter the physicochemical properties of nucleic acids in the extracellular environment. Strongly negatively charged nucleic acids bind to positively charged or electrically neutral carriers to form nanoscale complexes that more readily approach the cell membrane and are taken up. Some transfection reagents can also buffer protons during endosomal acidification or perturb membrane structure to facilitate endosomal escape, allowing nucleic acids to reach the cytoplasm or nucleus where they can act.At the same time, transfection reagents can partially protect nucleic acids from nuclease degradation. However, their cationic and surfactant-like properties inevitably exert some degree of stimulation and toxicity toward cells, so a balance must be struck between transfection efficiency and cellular safety.
1.3 Overall Differences Between Viral and Non-Viral Vectors
In terms of mechanism and carrier properties, transfection (or more broadly, gene delivery) systems can be divided into viral and non-viral vectors. Viral vectors exploit the natural infectivity of viruses, packaging exogenous genes into viral particles that bind to host-cell receptors for efficient entry. Non-viral vectors use artificially designed materials—lipids, polymers, nanoparticles—to form complexes with nucleic acids that enter cells mainly via endocytosis.Viral vectors excel in transduction efficiency and broad cell-type applicability, whereas non-viral vectors feature higher safety, simpler preparation, lower cost, and larger cargo capacity. In both research and clinical contexts, the two systems have distinct advantages and are often complementary.
II. Categories of Transfection Methods
2.1 Chemical Transfection
(1) Cationic polymer transfection (e.g., branched/linear PEI)
【Principle】
From the perspective of cell handling, cationic polymers such as PEI first bind rapidly to negatively charged nucleic acids to form positively charged nano-complexes. These complexes accumulate on the weakly negatively charged cell surface and are taken up by endocytosis. Subsequently, a fraction of the complexes escape from the endosomal–lysosomal pathway into the cytosol and may further enter the nucleus, allowing plasmid DNA, siRNA, and other cargos to mediate expression, silencing, or additional functions.
【Advantages】
PEI-type cationic polymers are readily available, inexpensive, and easy to prepare and store in solution. They can be reused for large-scale transfection, making them particularly suitable for transient overexpression, virus packaging, and other applications requiring processing of large cell numbers or construction of virus libraries. They show broad applicability to many common adherent cell lines and can achieve high nucleic acid uptake without specialized instrumentation, offering an overall favorable cost–performance ratio.
【Limitations and safety concerns】
Transfection efficiency and toxicity of PEI are highly sensitive to the N/P ratio, nucleic acid dose, buffer pH, and ionic strength, and different cell lines show markedly different tolerances. Suboptimal formulation or buffer conditions can easily cause pronounced cell death, morphological abnormalities, or functional impairment.
(2) Liposome/lipid nanoparticle (Lipid/LNP) transfection
【Principle】
From the viewpoint of delivery pathways, liposomes or LNPs form lipid–nucleic acid complexes by encapsulating or embedding nucleic acids within lipid structures, thus protecting them in the extracellular environment and concentrating them near the cell membrane. After uptake through membrane fusion or endocytosis, the complexes release nucleic acids into the cytosol during endosome maturation and acidification. RNA species such as mRNA and siRNA act directly in the cytoplasm, whereas plasmid DNA may enter the nucleus for gene expression.
【Advantages】
Optimized lipid and LNP formulations achieve high transfection efficiency in many adherent cell lines and some suspension cells. At appropriate doses, cytotoxicity tends to be relatively low, and compatibility with sensitive cell types such as stem cells and primary cells is generally good. These systems are particularly well suited for delivery of mRNA, siRNA, and antisense oligonucleotides (ASO), substantially enhancing nucleic acid stability and delivery efficiency. They have been widely applied in nucleic acid therapeutics and mRNA vaccine platforms and show good scalability and reproducibility in both in vitro and in vivo studies.
【Limitations and safety concerns】
Some high-performance lipid/LNP reagents are relatively expensive. Compositions and dosage windows must be systematically optimized for different cell lines and nucleic acid formats to avoid cell stress responses or latent toxicity. In vivo, lipid components may trigger complement activation, hepatotoxicity, or acute hypersensitivity, so injection route and dose must be rigorously evaluated and regulatory requirements strictly followed. Moreover, most lipid carriers remain non-integrating and therefore cannot by themselves guarantee long-term stable expression, often necessitating combination with viral vectors or gene-integration technologies.
2.2 Physical Methods and Viral Methods
(1) Electroporation
【Principle】
Electroporation applies a strong electric field across cells for an extremely short time, sharply increasing membrane potential and generating transient “electropores.” Driven by the electric field and concentration gradients, exogenous nucleic acids cross the membrane barrier into the cytosol. When the pulse ends, the membrane gradually reseals, while a fraction of nucleic acids remain within the cytosol or reach the nucleus, thereby accomplishing nucleic acid delivery and subsequent expression or genome editing.
【Advantages】
Electroporation is relatively independent of carrier format and can be applied to plasmid DNA, linear DNA, mRNA, siRNA, and CRISPR/Cas9 RNPs, among others. Even for “hard-to-transfect” cells—such as immune cells and hematopoietic stem cells—electroporation can often achieve high delivery efficiencies. It is widely used in cell-based immunotherapies (e.g., CAR-T cell preparation), primary cell functional studies, and in vitro genome editing. Once parameters are optimized, the method exhibits good reproducibility and is conducive to standardized manufacturing.
【Limitations and safety concerns】
Strong electric fields can cause irreversible membrane damage, leading to increased cell death, apoptosis, or functional impairment. Cell survival thus depends sensitively on voltage, pulse duration, pulse number, and composition of the electroporation buffer, and each cell type typically requires its own parameter optimization. Electroporation also relies on dedicated instruments and consumables, which are relatively costly. High-field operation introduces concerns regarding electrical safety and contamination control. Consequently, electroporation is better suited as a specialized tool for difficult transfections or clinically relevant workflows, rather than as the default method for all experiments.
(2) Viral transduction
【Principle】
Viral transduction uses gene-engineered, replication-deficient lentiviral, adenoviral, or adeno-associated viral (AAV) vectors whose pathogenic and replication-related genes have been deleted. Exogenous nucleic acids are packaged into viral capsids or particles, which then exploit natural receptor recognition, membrane fusion, or receptor-mediated endocytosis to efficiently enter target cells. Lentiviruses and other retroviral vectors can integrate exogenous genes into the host genome for long-term stable expression, whereas most adenoviruses and some AAV serotypes remain non-integrating or weakly integrating, making them more suitable for short- to medium-term strong expression or in vivo targeted delivery.
【Advantages】
Viral vectors retain the high infectivity of their parental viruses. They can achieve high levels of delivery and expression even in difficult primary cells, stem cells, neurons, and many tissues in vivo. Lentiviral systems are useful for generating stable cell lines, performing long-term functional studies, or conducting genetic screens. AAV vectors, which generally show lower immunogenicity, diverse serotypes, and broad tissue tropism, have unique advantages in in vivo gene therapy and gene regulation. Through selection of appropriate promoters, serotypes, and regulatory elements, it is possible to achieve cell type–specific and tunable expression patterns to some extent.
【Limitations and safety concerns】
Viral vector workflows—including plasmid construction, virus packaging, concentration, and titer determination—are complex and time-consuming, and overall costs are relatively high. They impose stringent requirements on biosafety level, operational procedures, and personnel training. Integrating vectors (such as lentiviruses) carry a potential risk of insertional mutagenesis and oncogene activation, which must be carefully considered in preclinical and clinical studies. Although non-integrating vectors pose lower genomic risk, viral proteins and their expression products may still elicit immune responses or neutralizing antibodies that compromise repeat dosing. In practice, viral dose and exposure duration must be tightly controlled, regulatory and ethical guidelines strictly followed, and appropriate safety designs (e.g., self-inactivating vectors, replication-deficient viruses) implemented when necessary.
III. Common Types of Chemical Transfection Reagents
3.1 Cationic Lipid-Based Transfection Reagents
(1) Mechanism of action
From the perspective of nanoparticle properties, cationic lipid transfection reagents use positively charged headgroups to bind negatively charged nucleic acids via electrostatic interactions, self-assembling into lipid–nucleic acid nanoparticles or liposomes in aqueous solution. The resulting particles accumulate near the cell membrane through surface charge and hydrophobic interactions and are taken up via membrane fusion or receptor-mediated endocytosis. Within endosomes, lipid components undergo conformational changes and lipid rearrangement, perturbing the membrane and promoting transfer of nucleic acids into the cytosol or nucleus. Particle size distribution, surface potential, and lipid composition/fluidity are key physical parameters for achieving efficient yet low-toxicity transfection.
(2) Application scenarios and features
Cationic lipid reagents typically yield high transfection efficiencies in adherent cell lines such as HEK293 and HeLa, and mature formulations can also be used for some suspension and primary cells. They are applicable to plasmid DNA, siRNA/miRNA, mRNA, and CRISPR-related nucleic acids. The protocols are straightforward and well suited to high-throughput experiments in multi-well plates. However, different cell lines display varying sensitivity to the same lipid reagent. Excessive dosing or overly long incubation readily causes cell rounding, detachment, and death. Thus, conditions must be pre-optimized for the specific cell type before formal experiments.
3.2 Polymer-Based Transfection Reagents
(1) Mechanism of action
From the standpoint of materials chemistry and structural parameters, polymer-based transfection reagents are usually composed of cationic polymers bearing multiple amine groups. The multiple positive charges distributed along the polymer chain progressively neutralize and condense nucleic acids in solution, forming relatively compact polymer–nucleic acid particles. After internalization, the “proton sponge effect” arising from the buffering capacity of the polymer during endosomal acidification leads to influx of ions and water, elevated osmotic pressure, and membrane disruption, thereby promoting nucleic acid release. Polymer molecular weight, branching, buffering capacity, and N/P ratio directly influence particle size, surface charge, and stability, which in turn determine intracellular trafficking and overall transfection performance.
(2) Advantages and limitations
Polymer-based transfection reagents are comparatively easy to synthesize and cost-effective, making them attractive for large-volume transfection and virus packaging in settings requiring substantial cell and nucleic acid quantities. In cell lines such as HEK293, they often perform well and are relatively tolerant of variations in ionic strength and serum content. However, some polymers display pronounced cytotoxicity at higher doses, causing apoptosis or necrosis and limiting their use in certain primary cells and stem cells. Toxicity can be mitigated by optimizing the N/P ratio, lowering the dose, or selecting modified polymer formulations.
3.3 Calcium Phosphate and Other Chemical Systems
(1) Calcium phosphate precipitation
Calcium phosphate transfection relies on co-precipitation of Ca²⁺ and DNA at specific pH and ionic strengths to form fine calcium phosphate particles. These particles slowly sediment under gravity and attach to the cell surface, then are taken up by endocytosis. This method uses inexpensive, readily available reagents and was once widely applied to gene expression and virus packaging in easy-to-transfect cells such as HEK293. However, the system is highly sensitive to pH and temperature; even slight deviations can alter particle properties and cause large fluctuations in transfection efficiency. Today it is used more for teaching demonstrations or projects with tight budgets.
(2) Specialized siRNA/mRNA/CRISPR reagents
Dedicated formulations have been developed for different nucleic acid types. siRNA-specific reagents emphasize achieving robust gene knockdown at low doses while minimizing off-target perturbations of the global transcriptome. mRNA transfection reagents use optimized lipids or polymers to enhance mRNA protection and delivery efficiency for rapid, transient protein expression. CRISPR-oriented reagents must accommodate delivery of Cas9 plasmids, mRNA, or RNPs, balancing editing efficiency against cytotoxicity and off-target risks. Such specialized reagents represent a shift from “one-size-fits-all” transfection tools toward application-tailored solutions.
IV. Factors Affecting Transfection Efficiency and Cytotoxicity
4.1 Cell-Related Factors
(1) Cell type and “easy-to-transfect” vs “difficult-to-transfect” cells
Different cell types can respond very differently to the same transfection reagent. Immortalized cell lines such as HEK293, HeLa, and CHO are generally considered easy to transfect, often achieving high efficiency with generic formulations. In contrast, immune cells, hematopoietic suspension cells, neurons, stem cells, and many primary cells are typically difficult to transfect and may require specialized reagents or alternative delivery methods such as electroporation. When evaluating strategies, one should consult the literature and manufacturer recommendations regarding compatible cell types.
(2) Cell status and density
Log-phase growth, absence of mycoplasma contamination, good nutritional status, and appropriate confluency all strongly influence outcomes. Transfections are commonly performed at 50–80% confluency to balance robust cell health with sufficient contact between cells and complexes. Very low densities lead to slow proliferation and poor cell condition, whereas overconfluence can cause nutrient limitations and elevated endogenous stress, both of which reduce efficiency and exacerbate toxicity. Maintaining low passage number, good morphology, and contamination-free cultures is fundamental for successful transfection.
4.2 Nucleic Acid-Related Factors
(1) Nucleic acid purity and structure
High-purity, low-salt, low-endotoxin plasmid DNA or RNA reduces nonspecific cellular stress and improves transfection efficiency. Plasmid topology also influences expression levels: supercoiled plasmids usually express more efficiently than linearized forms. RNA must be protected from repeated freeze–thaw cycles and RNase contamination. For mRNA, intact cap structure and poly(A) tail are crucial for translation efficiency and stability.
(2) Dose and construct design
Insufficient nucleic acid dosage leads to weak expression or knockdown, while excessive dosage elevates cytotoxicity and nonspecific effects. Promoters, enhancers, codon optimization, signal peptides, and tags all influence protein expression level and localization. siRNA/sgRNA sequence design dictates knockdown or editing efficiency and off-target risk. Using validated or well-optimized constructs at carefully titrated doses helps ensure robust phenotypes with minimal perturbation of overall cell physiology.
4.3 Reagent- and Protocol-Related Factors
(1) Reagent-to-nucleic acid ratio
Most transfection reagents specify recommended ranges for reagent/nucleic acid ratios, often in mass ratio or N/P ratio. In practice, small-scale pilot experiments around the recommended values are needed to identify optimal ratios for a given cell type and construct. Ratios that are too low lead to incomplete complex formation and poor efficiency; ratios that are too high produce excess free cationic carrier and markedly increased toxicity.
(2) Culture conditions and incubation time
Complex formation is sensitive to buffer composition, pH, and ionic strength, and many reagents require complexing in serum-free, low-protein environments. During cell incubation, conditions may be serum-containing or serum-free depending on the reagent’s instructions. Typical complex–cell incubation times range from 4 to 24 hours. Too short a time prevents sufficient uptake; excessively long exposure increases cellular burden. Timely replacement with fresh complete medium helps mitigate toxicity associated with prolonged exposure.
V. Major Application Areas of Transfection Reagents
5.1 Basic Molecular Biology Research
In basic molecular biology, transfection reagents are widely used in gene function analysis, signaling pathway studies, and protein expression and localization. Transfecting cells with plasmid DNA encoding a gene of interest enables observation of its effects on cellular phenotype and function, revealing roles in physiological and pathological processes. Transfection of siRNA or miRNA allows transient silencing of specific genes to study their functions from a “loss-of-function” perspective. Expression of fluorescently tagged proteins allows tracking of protein localization and dynamics within cells, providing experimental evidence for constructing signaling networks and regulatory circuits.
5.2 Gene Therapy and Cell Therapy
Gene therapy aims to treat genetic, neoplastic, and certain infectious diseases by introducing, repairing, or replacing genes, with transfection reagents serving as key components of gene delivery systems. Lentiviral vectors have entered clinical studies for certain hematologic and inherited disorders, while AAV vectors have achieved notable progress in ophthalmic diseases and coagulation disorders.Non-viral vectors, with higher biosafety and lower immunogenicity, are emerging as important research focuses in gene therapy, particularly for in vivo delivery of mRNA, siRNA, and CRISPR systems. They hold promise for enabling personalized and precision therapies through safer, more flexible gene delivery strategies.
5.3 Biopharmaceutical Production and Large-Scale Protein Expression
In biopharmaceuticals, transfection reagents are used to build and optimize recombinant cell factories for the production of monoclonal antibodies, recombinant proteins, and vaccines. Introducing genes encoding target proteins into CHO or HEK293 cells enables production of humanized proteins with correct folding and glycosylation. Efficient and stable transfection systems help increase expression levels, shorten process development timelines, and reduce manufacturing costs, thereby promoting the industrial-scale development of the biopharmaceutical sector.
VI. Related Products
Catalog No. | Product Name | Application |
Branched PEI Transfection Reagent (MW 25,000) | Transient plasmid DNA transfection in multiple mammalian cell lines; protein expression and virus packaging in HEK293, CHO, etc. | |
Linear PEI Transfection Reagent (MW 40,000), transfection grade | Cost-effective linear PEI reagent for plasmid DNA transfection and protein/virus production in 293 and CHO suspension or adherent cells | |
HEK293 Cell–Specific Transfection Reagent | High-efficiency plasmid DNA transfection optimized for HEK293/293T cells for high-level protein expression and lentiviral/AAV packaging | |
HP Nucleic Acid Transfection Reagent | General-purpose nucleic acid transfection reagent for plasmid DNA and siRNA/miRNA in various common mammalian cell lines | |
In vivo LNP RNA Local Transfection Kit | Construction of LNP delivery systems for local in vivo dosing of mRNA/siRNA (e.g., intratumoral, intramuscular, subcutaneous injection) | |
In vivo LNP RNA Systemic Transfection Kit | Preparation of LNP formulations suitable for intravenous injection for systemic in vivo delivery and multi-organ transfection of mRNA/siRNA | |
In vivo LNP Lung-Targeted RNA Transfection Kit | Lung-targeted LNP–RNA dosing (e.g., intravenous or intratracheal) for transfection of lung tissue/airway epithelial cells | |
In vivo LNP Liver-Targeted RNA Transfection Kit | Construction of liver-enriched LNP–RNA formulations for intravenous delivery and transfection of mRNA/siRNA into hepatocytes | |
LNP Ultra Short RNA Transfection Kit for Common Cells | LNP-mediated delivery of short RNAs (siRNA, miRNA, ASO) in common mammalian cells to enhance knockdown/regulation efficiency | |
LNP RNA Transfection Kit for Common Cells | LNP-based delivery of mRNA, sgRNA, and other RNAs in common cell lines for expression and editing experiments | |
LNP RNA Transfection Kit for Stem Cells | LNP–RNA transfection system optimized for stem cells (ESC, iPSC, MSC) for reprogramming, differentiation, and functional studies | |
LNP RNA Transfection Kit for Immune Cells | For RNA transfection in immune cell lines such as Jurkat, THP-1, DC2.4, U266, and RAW264.7, for applications including CAR design and screening and functional modification | |
LNP RNA Transfection Kit for Primary Immune Cells | LNP–RNA transfection specifically for primary immune cells (e.g., PBMCs, primary T cells), improving transfection efficiency | |
siRNA/miRNA Transfection Reagent | High-efficiency transfection of siRNA/miRNA and other small RNAs in various mammalian cells for gene-silencing experiments | |
Spleen-Targeted In vivo High-Efficiency Transfection Reagent | In vivo spleen-enriched nucleic acid delivery for gene expression or silencing in splenic immune cells | |
UltraBio™ 293F Transfection Reagent | High-efficiency transfection reagent optimized for suspension 293F cells for large-scale protein expression and virus production | |
UltraBio™ Insect Cell Transfection Reagent | Plasmid transfection and baculovirus system construction in insect cells such as Sf9, Sf21, and Hi5 | |
Liver-Targeted In vivo High-Efficiency Transfection Reagent | In vivo liver-targeted nucleic acid delivery via intravenous injection for gene expression or silencing in hepatocytes | |
Lung-Targeted In vivo High-Efficiency Transfection Reagent | In vivo lung-targeted nucleic acid delivery for gene function studies in respiratory disease models | |
High-Efficiency siRNA Transfection Reagent | siRNA-optimized high-efficiency transfection reagent for gene silencing in various common and some difficult-to-transfect cells | |
Transfection Reagent for Common Cells | General-purpose plasmid DNA transfection reagent for routine use in HEK293, HeLa, CHO, and other adherent cell lines | |
Universal Cell Transfection Reagent | DNA/RNA transfection reagent compatible with multiple cell lines and some primary cells for routine gene function and expression studies | |
High-Efficiency In vivo mRNA Transfection Reagent | High-efficiency in vivo delivery and transfection of mRNA in small animals for vaccine, protein replacement, and related studies | |
CHO Cell–Specific Transfection Reagent | Plasmid DNA transfection optimized for CHO-K1, CHO-S, and related CHO cells for antibody and recombinant protein expression | |
Insect Cell Transfection Reagent | General insect cell transfection reagent for plasmid delivery and baculovirus construction in Sf9/Sf21 cells | |
Liposome Transfection Reagent | Classical liposome-type DNA/RNA transfection reagent for transient or stable transfection in a variety of mammalian cells | |
Lentiviral Packaging Transfection Reagent | Transfection reagent optimized for HEK293T and other packaging cells for high-efficiency lentiviral vector transfection and high-titer virus production | |
transfection reagent | A new-generation cationic polymer transfection reagent suitable for gene transfection of primary cultured cells and transformed cell lines. | |
Lipo2000 Transfection Reagent | Suitable for transient or stable transfection of various adherent or suspension mammalian cells under serum or serum-free conditions. | |
DOTAP Transfection Reagent | Liposome transfection reagent based on the cationic lipid DOTAP, which can be used under serum or serum-free conditions to transfect DNA/RNA and other anionic molecules, enabling transient or stable gene expression in eukaryotic cells. |
Transfection reagents bridge the intracellular and extracellular environments for nucleic acids and are essential tools linking basic research with clinical translation. Whether for routine gene function studies, recombinant protein and antibody production, or cutting-edge applications in gene therapy, cell therapy, and nucleic acid drug development, efficient and safe transfection systems remain at the core.With the ongoing emergence of new lipid materials, polymeric carriers, and LNP platforms, transfection technologies are evolving toward higher efficiency, lower toxicity, improved targeting, and greater scalability. In parallel, transfection reagent product portfolios will continue to be refined to provide researchers and industry users with versatile, end-to-end solutions that support sustained innovation in molecular biology and gene therapy.
Aladdin: https://www.aladdinsci.com/